Oculis Holding AG (NASDAQ:OCS) Sees Significant Growth in Short Interest

Oculis Holding AG (NASDAQ:OCS) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 101,167 shares, a growth of 105.6% from the November 30th total of 49,197 shares. Based on an average trading volume of 95,845 shares, the days-to-cover ratio is currently 1.1 days. Currently, 0.2% of the shares of the company are short sold. Currently, 0.2% of the shares of the company are short sold. Based on an average trading volume of 95,845 shares, the days-to-cover ratio is currently 1.1 days.

Oculis Price Performance

Oculis stock traded down $0.19 during mid-day trading on Friday, hitting $20.50. The stock had a trading volume of 59,056 shares, compared to its average volume of 111,721. Oculis has a one year low of $14.00 and a one year high of $23.08. The company has a current ratio of 4.47, a quick ratio of 4.47 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $1.07 billion, a P/E ratio of -8.13 and a beta of 0.32. The firm’s 50 day moving average is $20.00 and its 200 day moving average is $18.89.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.10. The firm had revenue of $0.31 million during the quarter, compared to analyst estimates of $0.23 million. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%. On average, sell-side analysts forecast that Oculis will post -2.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Oculis

Hedge funds have recently modified their holdings of the stock. Bosun Asset Management LLC bought a new position in shares of Oculis during the second quarter worth $378,000. Marshall Wace LLP bought a new position in shares of Oculis during the 2nd quarter valued at about $393,000. Geode Capital Management LLC grew its position in shares of Oculis by 27.7% during the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after purchasing an additional 6,384 shares in the last quarter. Bank of America Corp DE grew its position in shares of Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after purchasing an additional 878 shares in the last quarter. Finally, Woodline Partners LP increased its holdings in shares of Oculis by 65.8% in the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after purchasing an additional 33,265 shares during the last quarter. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on OCS shares. HC Wainwright raised their price target on Oculis from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Stifel Nicolaus increased their target price on Oculis from $35.00 to $40.00 and gave the company a “buy” rating in a report on Friday, December 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research note on Wednesday, October 8th. Bank of America reduced their price target on shares of Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. Finally, Lifesci Capital started coverage on shares of Oculis in a report on Wednesday, December 3rd. They issued an “outperform” rating and a $55.00 price objective on the stock. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $41.50.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.